Prophase Labs

PRPH · NASDAQ

$0.0094+$0.0009 (+10.59%)TodayMarket closed ·
Prev close $0.0085

About PRPH

ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. The company is headquartered in New York City, New York. The firm is engaged in providing whole genome sequencing solutions, diagnostic development, such as its potentially life-saving test for the early detection of esophageal cancer and a direct-to-consumer marketing platform for OTC dietary supplements. The company develops, manufactures, and commercializes health and wellness solutions. Its Diagnostic services segment provides diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. Its Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and provides personal genomics products and services. The firm also develops and markets dietary supplements under the TK Supplement brand, which includes Legendz XL and Triple Edge XL.

Employees
96
Headquarters
New York City, New York
Listed
Jan 16, 1984
Sector
Health Care
Industry
Pharmaceuticals

PRPH key statistics

Market cap
170.33K
Price-earnings ratio
0.00
Dividend yield
—
Average volume
490.80K
Volume
1.64M
Open price
$0.0092
High today
$0.01
Low today
$0.009
52 Week high
$5.36
52 Week low
$0.008

Prophase Labs (PRPH) at a glance

As of Oct 20, 2026, Prophase Labs (PRPH) shares are priced at $0.0094, giving the company a market cap of 170.33K and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.009 and $0.01. The current price is 4.4% above the day's low and 6.0% below its high.

Volume so far is 1.64M shares, above the average of 490.80K shares a day.

Over the past year Prophase Labs has ranged from $0.008 to $5.36, and now sits 0% of the way up that range.

Prophase Labs met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY25 it reported -$1.10 per share against an estimate of -$1.53.

PRPH earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 42.4% on average.

  1. Q3 FY23: reported -$3.00 per share against an estimate of -$1.99
  2. Q4 FY23: reported -$5.10 per share against an estimate of -$2.65
  3. Q1 FY24: reported -$0.70 per share against an estimate of -$2.86
  4. Q2 FY24: reported -$3.30 per share against an estimate of -$2.50
  5. Q3 FY24: reported -$3.50 per share against an estimate of $0.408
  6. Q4 FY24: reported -$15.90 per share against an estimate of -$2.45
  7. Q1 FY25: reported -$1.40 per share against an estimate of -$1.84
  8. Q2 FY25: reported -$1.10 per share against an estimate of -$1.53

PRPH news

  • Avi Kapoor

    Dow Gains Over 200 Points; Conagra Shares Fall After Q2 Results

  • Press releaseGlobe Newswire

    From Super Fibers to Super Deals: Science, Scale, and Strategic Capital Shape the Morning Tape

  • 12 Health Care Stocks Moving In Tuesday's Intraday Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • A Peek at ProPhase Labs's Future Earnings

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releasePRNewswire

    Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Similar companies

Companies in the same industry as Prophase Labs

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.